Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 1 1

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Carcinoma, Transitional Cell 24Urinary Bladder Neoplasms 22Ureteral Neoplasms 8Urologic Neoplasms 4Urethral Neoplasms 3Parkinson Disease 4, Autosomal Dominant Lewy Body 3Neoplasms 3Neoplasm Metastasis 3Peripheral Nervous System Diseases 2Muscle Invasive Bladder Urothelial Carcinoma 2Metastatic Urothelial Cancer 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2Advanced Bladder Cancer 2Urothelial Cancer 1Urologic Diseases 1Urogenital Neoplasms 1Urogenital Diseases 1Urinary Bladder Diseases 1Urachal adenocarcinoma 1Triple Negative Breast Neoplasms 1Salivary Gland Neoplasms 1Renal Pelvis and Ureter Urothelial Carcinoma 1Penile Squamous Cell Carcinoma (PSCC) 1Penile Neoplasms 1Pancreatic Neoplasms 1Non-Muscle Invasive Bladder Neoplasms 1Neoplasms by Site 1Muscle-invasive Bladder Cancer 1Metastatic Urothelial Cancer and Other Malignant Solid Tumors 1

Interventions

Acupuncture Therapy 10Exercise 7Cryotherapy 6Paclitaxel 5Glutamine 5Surveys and Questionnaires 3Duloxetine Hydrochloride 3Dexamethasone 3Bortezomib 3Acetylcysteine 3pembrolizumab 2enfortumab vedotin 2Thioctic Acid 2Tablets 2Sodium Chloride 2Saline Solution 2Physical Therapy Modalities 2Low-Level Light Therapy 2Fish Oils 2Fatty Acids, Omega-3 2ziconotide 1sagopilone 1nicotinamide-beta-riboside 1nabilone 1glutamic acid diethyl ester 1allantoicase 1Yoga 1XELOX 1Vitamin D 1Vitamin B Complex 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Peripheral Nervous System Diseases × enfortumab vedotin × Clear all
NCT07629700 2026-06-05

ENDEAVOR

University of Florence

Phase NA Not yet recruiting
40 enrolled
Genitourinary

Carcinoma, Transitional Cell, Peripheral Nervous System Diseases

NCT07484022 2026-06-03

Study of GB-4362 With Enfortumab Vedotin and Pembrolizumab for Advanced Urothelial Cancer

Generate Biomedicines

Phase 1 Recruiting
37 enrolled
Genitourinary

Carcinoma, Transitional Cell, Peripheral Nervous System Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡